Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Thursday, September 16, 2021 10:23:58 AM
1. Whether One, Two, Three or 1,000 employees...THE VALUE OF IPIX is in the Value of the INTELLECTUAL PROPERTIES (COMPOUNDS - Brilacidin and Kevertrin) it is moving through CLINICAL TRIALS...
2. BP buys INTELLECTUAL PROPERTIES...With successful trials...and if necessary, ONLY KEY SCIENTIFIC PERSONNEL. IMO they will probably give DeGrado a huge consulting contract or make an offer to join them in the C suite that he can't refuse. (IMO Leo and LONG investors will go off in the sunset with a spectacular return on Covid-19/Variant indication alone.
3. LEO and staff with "Contract" Personal have done an excellent job in progressing to and through SUCCESSFUL BRILACIDIN PHASE II CLINICAL TRIALS...for UP, UC, OM, ABSSSI and in raising funds ($13M-16M) to COMPLETE and REPORT on Covid-19 Trials, as well as funding product development for the other indications. IMO ...we are days away from revealing SUCCESS in destroying ... COVID-19 and its Variants in the trials. IPIX IS FAR FROM A ONE-TRICK PONY!
4. NO CEO or CHAIRMAN of a PUBLICALLY TRADED BIOTEC COMPANY is personally liable for an Unsuccessful Clinical Trial... IF THAT WERE THE CASE...IF THE RIDICULOUS ASSERTION FROM DETRACTORS OF IPIX/LEO WERE TRUE...WE WOULD NEVER HAVE A BIOTECH COMPANY CONDUCTING EVEN ONE CLINICAL TRIAL!
5. ALL PR's by IPIX (LEO) on Brilacidin/Covid-19 trials were fact-based reporting on RBLS TEST RESULTS, Developers Hypothesis, as well as previous commentary regarding SUCCESSFUL PHASE II TRIALS ON OTHER INDICATIONs and BRILACIDIN's path to probable SUCCESS...in /COVID-19 Clinical Trials...NO EXAGGERATION...(LEO IS NOT STUPID!)...
...and most importantly...IMO it is very likely the FDA would not permit the publishing of PR's which were not fact-based and consistent with what is known about Brilacidin's attributes at the time of publication. With all the censorship around Covid-19/Vaccines/Therapies...if ANYTHING stated wwere not FACTUAL...IMO FDA would have not permitted the PR or sanctioned IPIX with a C*YD treatment.
Know what you own!
ps for those who care...I believe the religious holiday ends today at sunset...Tomorrow could be interesting...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM